TFA Therapeutics, Inc.
RAJAF · OTCMCIK 1885680fmd_0KZV3XJWYKK106MJZMDXTFP75KManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2021 to Dec 31, 2025, 7 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 1 | 1 | 1 |
| Cost of revenue | 1 | 0 | 0 | 0 | 0 |
| Gross profit | (0) | 0 | 1 | 1 | 1 |
| Realized investment gains (losses) | – | – | 1 | – | – |
| Net interest income after provision | (0) | (1) | – | – | – |
| Research and development | 0 | 0 | – | – | – |
| Compensation and benefits | 0 | 0 | 0 | – | – |
| Total operating expenses | 0 | 0 | 1 | 1 | 1 |
| Operating income | (0) | (0) | 0 | (0) | (0) |
| Interest expense | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | 0 | 0 | (0) | (0) | (0) |
| Income before taxes | (0) | (0) | 0 | (0) | (0) |
| Income tax expense | 0 | 0 | 0 | 0 | – |
| Net income from continuing operations | (0) | (0) | 0 | (0) | (0) |
| Net income | (0) | (1) | 1 | (0) | (0) |